Skip to main content
main-content

The independent medical news service

Melanoma

30-10-2018 | Oncology | News | Article

ESMO 2018

Continued benefits of immunotherapy shown in advanced melanoma

An updated analysis of the CheckMate 067 trial shows continued survival benefits at 4 years with nivolumab plus ipilimumab or nivolumab monotherapy versus ipilimumab alone in patients with previously untreated advanced melanoma.

Source:

ESMO 2018; Munich, Germany; 19–23 October
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30700-9
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30753-8

18-10-2018 | Melanoma | News | Article

Neoadjuvant checkpoint blockade investigated in high-risk melanoma

In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.

Source:

Nat Med 2018; doi:10.1038/s41591-018-0197-1

14-09-2018 | Oncology | Main feed | News

approvalsWatch

EMA supports encorafenib plus binimetinib combination

Read more here

07-09-2018 | Melanoma | News | Article

FDG-PET predicts metastatic melanoma outcomes better than CT imaging

Using 18F-fluorodeoxyglucose–positron emission tomography to measure treatment response at 1 year in patients with metastatic melanoma may better predict long-term outcomes than standard computed tomography, research shows.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy330

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy263

10-08-2018 | Oncology | News | Article

Adjuvant bevacizumab not recommended for melanoma, HER2-negative breast cancer

The AVAST-M and E5103 trial results rule out the use of bevacizumab in the adjuvant setting in high-risk patients with cutaneous melanoma and HER2-negative breast cancer, respectively.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy229
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.2028

17-07-2018 | Melanoma | News | Article

‘Dramatically improved’ OS with checkpoint inhibitor use for melanoma brain metastases

Melanoma patients with brain metastases can expect to live longer following the incorporation of checkpoint inhibitors and BRAF-targeted therapies into standard care than their counterparts treated prior to the approval of these agents, suggests an analysis of the US National Cancer Database.

Source:

Cancer Immunol Res 2018; doi:10.1158/2326-6066.CIR-18-0067

12-07-2018 | Oncology | News | Article

High glucocorticoid doses may negatively impact CTLA-4 inhibitor efficacy

Researchers recommend against the routine use of high-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis inpatients with melanoma after observing poorer oncologic outcomes with high versus low doses.

Source:

Cancer 2018; doi:10.1002/cncr.31629, 10.1002/cncr.31627

05-07-2018 | Oncology | News | Article

approvalsWatch

Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

Find out more about this US FDA decision here

18-06-2018 | Melanoma | News | Article

ASCO 2018 in brief

COLUMBUS OS data favor encorafenib–binimetinib for advanced BRAF-mutated melanoma

An updated analysis of the phase III COLUMBUS trial adds to the evidence supporting a combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib in patients with advanced BRAF V600-mutant melanoma.

17-05-2018 | Oncology | News | Article

Editor's pick

Cancer immunotherapy efficacy may vary by sex

The magnitude of the survival benefit associated with immune checkpoint inhibitor treatment appears to be sex dependent, with women benefiting less than men, according to a meta-analysis published in The Lancet Oncology.

Source:

Lancet Oncol 2018; Advance online publication

02-05-2018 | Oncology | Main feed | News

approvalsWatch

Adjuvant dabrafenib–trametinib approved for mutated melanoma

Read more on this US FDA decision here

23-04-2018 | Melanoma | News | Article

Editor's pick

Encorafenib–binimetinib a new option for BRAF-mutated melanoma

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate.

Source:

Lancet Oncol 2018; Advance online publication

17-04-2018 | Melanoma | News | Article

Pembrolizumab delays recurrence in high-risk stage III melanoma

Adjuvant pembrolizumab significantly improves recurrence-free survival, compared with placebo, when given to patients with high-risk stage III melanoma for up to 1 year, researchers report in The New England Journal of Medicine.

Source:

AACR 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

22-02-2018 | Melanoma | News | Article

ctDNA flags up pseudoprogression during melanoma treatment

Circulating tumor DNA can differentiate pseudoprogression from true disease progression in patients with metastatic melanoma undergoing immunotherapy, a study suggests.

Source:

JAMA Oncol 2018; Advance online publication

26-01-2018 | Melanoma | News | Article

Neoadjuvant therapy may benefit patients with high-risk melanoma

Receiving neoadjuvant plus adjuvant dabrafenib and trametinib significantly improves event-free survival compared with standard care in patients with high-risk melanoma, phase II study findings indicate.

Source:

Lancet Oncol 2018; Advance online publication

15-01-2018 | Oncology | News | Article

Risks of combining immunotherapy with targeted therapy, radiation highlighted

Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology.

Source:

JAMA Oncol 2018; Advance online publication

09-01-2018 | Melanoma | News | Article

Pembrolizumab discontinuation feasible in metastatic melanoma

Patients with metastatic melanoma who achieve a complete response with pembrolizumab therapy have a low risk for disease progression or death, report researchers who believe that treatment discontinuation is possible in this setting.

Source:

J Clin Oncol 2017; Advance online publication

05-01-2018 | Oncology | News | Article

In other news

Here we cover a study exploring the effects of age on melanoma immunotherapy outcomes and two clinical trials, one assessing anamorelin in patients with non-small-cell lung cancer-related cachexia and the other investigating a novel fibroblast growth factor receptor kinase inhibitor in the advanced cholangiocarcinoma setting.

30-11-2017 | Melanoma | News | Article

News in brief

Checkpoint inhibitors, targeted therapies boost advanced melanoma OS in USA

The overall survival of patients with stage IV melanoma has improved on a national scale since the approval of the first-in-class immune checkpoint and BRAF inhibitors, according to a US National Cancer Database analysis.

image credits